PE-0139(PE-0139) - 药物靶点：INSR_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

Insumera

靶点

INSR

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

PhaseBio Pharmaceuticals, Inc.

在研机构-

非在研机构

PhaseBio Pharmaceuticals, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 4868

Sequence Code 528239895

关联

2

项与 PE-0139 相关的临床试验

NCT02581657

/ Completed临床2期

Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.

开始日期2015-10-01

申办/合作机构

PhaseBio Pharmaceuticals, Inc.

NCT01835730

/ Completed临床1期

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).

开始日期2013-04-01

申办/合作机构

PhaseBio Pharmaceuticals, Inc.

100 项与 PE-0139 相关的临床结果

登录后查看更多信息

100 项与 PE-0139 相关的转化医学

登录后查看更多信息

100 项与 PE-0139 相关的专利（医药）

登录后查看更多信息

100 项与 PE-0139 相关的药物交易

登录后查看更多信息